Shaolin Capital Management’s Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 CLDI.WS Stock Holding History

Shaolin Capital Management's CLDI.WS Position: Q4 2024 in Review

Shaolin Capital Management sold out of Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) in Q4 2024, closing a stake of 330,547 shares — an estimated $4.33K sold.

Shaolin Capital Management first reported a position in CLDI.WS in Q1 2022 and held it in 10 quarters. The position peaked at $179K in Q1 2022. 1 fund tracked by Wall St. Rank holds CLDI.WS as of Q4 2024.

• Shaolin Capital Management reported no remaining Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 position as of Q4 2024 after selling out during the quarter.
• Shaolin Capital Management sold 330,547 Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 shares in Q4 2024, an estimated $4.33K.
• Shaolin Capital Management first reported a position in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 in Q1 2022 and held it in 10 quarters.
• Shaolin Capital Management's Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 position peaked at $179K in Q1 2022.
• 1 fund tracked by Wall St. Rank held Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 as of Q4 2024.

Based on Shaolin Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.